Allan Miller
Medical Oncology · Grand Junction, CONPI 1053375675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,328 and has fallen 94.6% since, to $71 in 2023.
Across 78 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$172
- AstraZeneca$168
- Novartis$164
- Astellas Pharma US Inc$120
- Merck$118
- E.r. Squibb & Sons, L.L.C.$100
- plus $615 from 18 others
Across 6 payments — averaging $7491.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$29K
- Seagen Inc.$16K
What the payments were for
- Food & beverage$1,44699%
- Education$101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 13 | $172 |
| AstraZeneca(2 entities) | 4 | $168 |
| Novartis | 10 | $164 |
| Astellas Pharma US Inc | 1 | $120 |
| Merck | 10 | $118 |
| E.r. Squibb & Sons, L.L.C. | 4 | $100 |
| Amgen | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Seagen Inc. | 3 | $51 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $47 |
| Sanofi | 2 | $41 |
| Genentech USA, Inc. | 2 | $36 |
| Bristol Myers Squibb | 2 | $35 |
| Verastem, Inc. | 2 | $34 |
| Pfizer | 2 | $27 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $26 |
| Tesaro, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $24 |
| Clovis Oncology, Inc. | 2 | $24 |
| Myovant Sciences Inc. | 1 | $21 |
| Exelixis Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$120
How this compares
$1,456 in reported general payments places this provider in the 55th percentile of 96 medical oncology providers in Colorado.
Other medical oncology in Grand Junction
- Jonathan KingGrand Junction$4K
- Kristina GoutsouliakGrand Junction$1K
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Chelsea GawryletzFort Collins$301K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.